| Objective To evaluate the efficacy of autologous DC-CIK(dendritic cell-cytokine-induced killer) cells in combination with regional hyperthermia in patients with chemotherapy-resistant lung cancer malignant pleural effusion.Methods A total of 52 patients with chemotherapy-resistant lung cancer eceived autologous DC-CIK cells plus regional hyperthermia and 22 patients received regional hyperthermia only. The DC-CIK cells were transfused once per day for 4 consecutive days at 1.0~1.2 x 109 per dosage,while regional hyperthermia was conducted for 60 minutes on the first、fourth day. Tlymphocyte subpopulations in peripheral blood and pleural effusion were measured and analyzed.Results The statuses of T lymphocyte subpopulations were improved in patients after treatment with autologous DC-CIK cells plus regional hyperthermia when compared with those treated with regional hyperthermia only. Their response rates were 46.7% and 13.6%,respectively(p<0.05), and life quality improvement rates were 66.7% and 18.2%(p<0.05), respectively.Conclusion The intracavitary administration of autologous DC-CIK cells plus regional hyperthermia is an effective and tolerant way to treat patients with chemotherapy-resistant lung cancer malignant pleural effusion, suggesting that treatment with autologous DC-CIK cells improves the ability of the anti-tumor effect of natural immunity. |
PDF Full Text Request